BFEC
CERE

Benjamin F. Edwards & Company’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Benjamin F. Edwards & Company’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$3K Sell
80
-102
-56% -$4.25K ﹤0.01% 2011
2024
Q1 		$8K Buy
+182
New +$7.64K ﹤0.01% 1762

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Benjamin F. Edwards & Company's CERE Position: Q2 2024 in Review

Benjamin F. Edwards & Company reduced its Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) stake by 56% in Q2 2024, selling an estimated $4.25K and leaving 80 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #2011.

Benjamin F. Edwards & Company first reported a position in CERE in Q1 2024 and has held it in 2 quarters since. The position peaked at $8K in Q1 2024. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • Benjamin F. Edwards & Company held 80 shares of Cerevel Therapeutics Holdings, Inc. Common Stock worth $3K as of Q2 2024.
  • Benjamin F. Edwards & Company sold 102 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $4.25K.
  • Cerevel Therapeutics Holdings, Inc. Common Stock made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #2011 holding.
  • Benjamin F. Edwards & Company first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and has held it in 2 quarters since.
  • Benjamin F. Edwards & Company's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $8K in Q1 2024.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.